CN Patent

CN114469991A — 用于治疗睑板腺功能障碍的二硫化硒组合物

Assigned to Mg Therapeutics Ltd · Expires 2022-05-13 · 4y expired

What this patent protects

本文描述了用于治疗睑板腺功能障碍的组合物和方法。所述方法通过施用包含二硫化硒和无水半固体基质的所述组合物进行。稳定的无水组合物基本上不含二硫化硒附聚物。

USPTO Abstract

本文描述了用于治疗睑板腺功能障碍的组合物和方法。所述方法通过施用包含二硫化硒和无水半固体基质的所述组合物进行。稳定的无水组合物基本上不含二硫化硒附聚物。

Drugs covered by this patent

Lignospan Forte (Lidocaine Hydrochloride) · Fresenius Kabi

Patent Metadata

Patent number: CN114469991A
Jurisdiction: CN
Classification: —
Expires: 2022-05-13
Drug substance claim: No
Drug product claim: No
Assignee: Mg Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.